Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung scarring: SOLIS trial tests H01 drug

NCT ID NCT06325696

Recruiting now Disease control Sponsor: National Institute of Environmental Health Sciences (NIEHS) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests a drug called H01 (hymecromone) in adults with interstitial lung disease, a condition that causes lung scarring and makes breathing hard. The goal is to see if H01 can lower a marker of lung damage and improve lung function. Participants take the drug as a tablet twice daily for 12 weeks and attend clinic visits for tests like breathing tests and a 6-minute walk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis interstitial lung disease lung disorder pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS INTERSTITIAL LUNG DISEASE LUNG DISEASES, INTERSTITIAL

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NIEHS Clinical Research Unit (CRU)

    RECRUITING

    Research Triangle Park, North Carolina, 27709, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••